The effect of fluoxetine on anxiety and depression symptoms in cancer patients

Razavi, Darius; Allilaire, J. F.; Smith, Mark A.; Salimpour, A; Verra, Martin L.; Desclaux, Bernard; Saltel, P.; Piollet, I.; Gauvain-Piquard, A.; Trichard, Christian; Cordier, B.; Fresco, Roberto; Guillibert, E.; Sechter, D.; Orth, JP; Bouhassira, M.; Mesters, P.; Blin, Patrick

doi:10.1111/j.1600-0447.1996.tb09850.x

Cited by 142 publications

(107 citation statements)

References 10 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Chronic treatment with antidepressants, including fluoxetine, has been found to be effective in alleviating the depression associated with multiple sclerosis (Schiffer and Wineman 1990), stroke (Lauritzen et al 1994), HIV infection (Rabkin et al 1994), cancer (Razavi et al 1996), and neurodegenerative diseases (Alexopoulos 1996). Because these medical conditions are also associated with dramatic immune activation and cytokine secretion (Dinarello and Wolff 1993;Rothwell et al 1996;Yirmiya et al 1999), it may be suggested that at least part of the effects of fluoxetine (and possibly other antidepressants) in these conditions is in attenuating sickness behavior symptoms.…”

Section: Discussionmentioning

confidence: 99%

Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents

Yirmiya

Pollak

Barak

et al. 2001

Neuropsychopharmacology

203

View full text Add to dashboard Cite

Antidepressants produce various immunomodulatory effects, as well as an attenuation of the behavioral responses to immune challenges, such as lipopolysaccharide (LPS). To explore further the effects of antidepressants on neuroimmune interactions, rats were treated daily with either fluoxetine (Prozac) or saline for 5 weeks, and various behavioral, neuroendocrine, and immune functions were measured following administration of either LPS or saline. Chronic fluoxetine treatment significantly attenuated the anorexia and body weight loss, as well as the depletion of CRH-41 from the median eminence and the elevation in serum corticosterone levels induced by LPS. Chronic treatment with imipramine also attenuated LPS-induced adrenocortical activation. In rats and in mice, which normally display a biphasic body temperature response to LPS (initial hypothermia followed by hyperthermia), chronic treatment with fluoxetine completely abolished the hypothermic response and facilitated and strengthened the hyperthermic response. The effects of antidepressants on the responsiveness to LPS are probably not mediated by their effects on peripheral proinflammatory cytokine production, because LPS-induced expression of TNFSeveral lines of evidence indicate that antidepressants produce various immunomodulatory effects. In depressed patients, the effects of antidepressants are variable and seem to be related to the immune status of the patients at the initiation of the treatment. When depression was associated with immune activation, antidepressants reduced immune function and cytokine secretion. For example, the increased plasma levels of IL-6 during acute depression were normalized by 8-week treatment with fluoxetine (Sluzewska et al. 1995), the increased monocyte counts in depressed patients were reduced following 6-weeks treatment with tricyclic antidepressants (TCAs) (Seidel et al. 1996), and the increased numbers of leukocytes and neutrophils were also reduced by antidepressant treatment (Maes et al. 24 , NO . 5 1997). On the other hand, when immune functions were found to be normal, antidepressants had no immunological effects; for example, chronic moclobemide treatment had no effect on monocytes functions, TNF ␣ production or IFN ␥ levels (Landmann et al. 1997). Moreover, in a study of depressed patients who exhibited immune suppression before treatment, the TCA clomipramine increased the production of IL-1 ␤ , IL-2, and IL-3 (Weizman et al. 1994).In experimental animals, TCAs as well as selective serotonin reuptake inhibitors (SSRIs) produce mainly immune suppression and anti-inflammatory effects. For example, antidepressant treatment in vivo inhibited the increased acute phase response in olfactory bulbectomized rats, a useful animal model of depression (Song and Leonard 1994), reduced the production of interleukin-1 (IL-1) and IL-2 in a chronic mild stress model of depression (Kubera et al. 1996), inhibited immune activation in rats with experimental allergic neuritis (Zhu et al. 1994), and produced anti-inflammatory ...

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents

Yirmiya

Pollak

Barak

et al. 2001

Neuropsychopharmacology

203

View full text Add to dashboard Cite

show abstract

“…fluoxetine and paroxetine) 71 as well as tricyclic antidepressants (TCAs; e.g. amitriptyline and desipramine) 74 . In addition, some antidepressants (e.g.…”

Section: Use Of Antidepressants and Cancermentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

261

179

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is common among cancer patients, with prevalence rates up to four-times higher than the general population. Depression confers worse outcomes, including non-adherence to treatment and increased mortality in the oncology setting. Advances in the understanding of neurobiological underpinnings of depression have revealed shared biobehavioral mechanisms may contribute to cancer progression. Moreover, psychosocial stressors in cancer promote:(1) inflammation and oxidative/nitrosative stress; (2) a decreased immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous system and of the hypothalamic-pituitary-adrenal axis. Consequently, the prompt recognition of depression among patients with cancer who may benefit of treatment strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances, is a public health priority. Moreover, behavioral strategies aiming at reducing psychological distress and depressive symptoms, including addressing unhealthy diet and life-style choices, as well as physical inactivity and sleep dysfunction, may represent important strategies not only to treat depression, but also to improve wider cancer-related outcomes. Herein, we provide a comprehensive review of the intertwined biobehavioural pathways linking depression to cancer progression. In addition, the clinical implications of these findings are critically reviewed.

show abstract

“…Between half to 100% of participants were female. Three studies were multicentre trials (Razavi et al, 1996;Fisch et al, 2003;Morrow et al, 2003) and three were single-centre trials (Van Heeringen and Zivkov, 1996;Musselman et al, 2001;Roscoe et al, 2005).…”

Section: Pharmacological Studiesmentioning

confidence: 99%

“…The six pharmacological studies were randomised placebocontrolled trials conducted in the United States of America (n ¼ 4) (Musselman et al, 2001;Fisch et al, 2003;Morrow et al, 2003;Roscoe et al, 2005) and Belgium (n ¼ 2) (Razavi et al, 1996; Box 1 Search strategy terms Van Heeringen and Zivkov, 1996). The mean sample size of intervention and control groups was 83 (range 20 -277 patients) and 83 (range 20 -272 patients), respectively.…”

Section: Pharmacological Studiesmentioning

confidence: 99%

The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review

2006

View full text Add to dashboard Cite

Depression is common in cancer patients, and this often remains undetected and untreated. Depression has been associated with poorer quality of life, in addition to increased impairment of immune response and poorer survival in cancer patients. Previous systematic reviews and meta-analyses of the efficacy of interventions for cancer patients with depression have failed to distinguish between caseness for depression and depressive symptoms. The findings from this systematic review show that there is limited trial data on the efficacy of prescribed antidepressants in reducing the incidence of major depression and depressive symptoms in cancer patients. Contrary to previous reviews that failed to distinguish between depressive symptoms and depression, this review found very little data from clinical trials (without the possibility of confounding factors) to demonstrate that psychotherapeutic interventions are effective in reducing depression in cancer patients. A number of small-scale, single-centre trials indicated that psychotherapeutic interventions (especially cognitive behavioural therapy) can have effects on depressive symptoms in cancer patients. However, given the methodological limitations of studies to date, lack of evidence should not be interpreted as implying lack of efficacy. In conclusion, there is a need for adequately powered studies of pharmacological and psychotherapeutic studies, which are targeted at cancer patients with a diagnosis of depression and include monitoring of the use of other pharmacological/psychotherapeutic and complementary and alternative medicine interventions.

show abstract

The effect of fluoxetine on anxiety and depression symptoms in cancer patients

Cited by 142 publications

References 10 publications

Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents

Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents

Depression in cancer: The many biobehavioral pathways driving tumor progression

The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review

Contact Info

Product

Resources

About